Why is Neil Woodford so bullish on drugmakers GlaxoSmithKline plc, AstraZeneca plc and 4D Pharma plc?

Will GlaxoSmithKline plc (LON: GSK), AstraZeneca plc (LON: AZN) and 4D Pharma plc (LON: DDDD) be the cure for poor returns?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Neil Woodford’s Equity Income Fund is heavily weighted towards healthcare companies, and GlaxoSmithKline (LSE: GSK) makes up 6.3% of this entire fund. Woodford hasn’t only been buying the company for its 5%-plus dividend though, but also sees great value in the company being broken up. This is a common refrain among fund managers as GSK CEO Sir Andrew Witty has bucked the recent consensus amongst pharma giants and charted a path towards more reliance on consumer healthcare goods such as toothpaste and over-the-counter flu treatments.

These consumer-facing goods now bring in nearly 30% of GSK’s revenue, but their 17% operating margins significantly lag the 32% brought in by pharmaceuticals or 29% from vaccines. While 17% margins are nothing to sneer at, they do bring down group performance, which is especially galling for some investors as GSK’s new HIV drugs finally enter the market and bring in significant revenue. However, Witty’s turnaround is beginning to bear fruit as earnings are expected to increase at a low-double-digits clip this year and will once again cover solid dividends.

Changing business model

AstraZeneca (LSE: AZN) is another major holding in Woodford’s income fund thanks to the company’s 4.7% yielding dividend. AstraZeneca, like many of its American counterparts, has doubled down on high-risk-but-high-profit speciality drugs. CEO Pascal Soriot sees the company’s future in designing targeted cancer treatments for a smaller subset of the population. This requires a smaller sales force than the company currently boasts, which will bring down operating costs but also require higher R&D spending.

This shift in business model comes as the company lost its US patents to Nexium in 2014 and will lose Crestor patents this year, which management is expecting to bring earnings down in the mid-single-digits. These two drugs combined brought in roughly a third of revenue in prior years, so generic competition will impact the bottom line for several years to come. Despite this, the growth areas now bring in 56% of revenue and the company has a well-stocked pipeline after spending over $6.2bn on acquisitions in the past two years alone. Looking forward, the company’s long-term focus on high margin oncology treatments makes good sense and the company has an enviable pipeline of new drugs to tide it over in the short term as earnings fall due to generic competition.

A risk too far

With no revenue whatsoever, small cap 4D Pharma (LSE: DDDD) is a far cry from GSK or AstraZeneca, yet Woodford owns nearly 24% of the company’s outstanding shares. 4D is a major bet on the viability of using beneficial bacteria to treat diseases ranging from asthma to multiple sclerosis. So far, the company has acquired a bevy of small drugs developers and now has 15 drugs in development with two currently in patient trials and three more expected to begin them this year.

After two share placements, the company had £85.4m in cash at year-end, which should fund operations and acquisitions for several years to come. 4D is one to watch then, but the risks of investing in a company with no revenue that relies on issuing shares to fund development is too risky a prospect for me until results from more clinical trials are released.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ian Pierce has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Photo of a man going through financial problems
Investing Articles

Is a stock market crash coming? And what should I do now?

Global investors are panicking about a new US stock market crash in the days or weeks ahead. Here's how I'm…

Read more »

Investing Articles

FTSE shares: a brilliant opportunity for investors to get rich?

With valuations in the US looking full, Paul Summers thinks there's a good chance that FTSE stocks might become more…

Read more »

Growth Shares

2 FTSE 100 stocks that could outperform the index in 2025

Jon Smith flags up a couple of FTSE 100 stocks that have strong momentum right now and have beaten the…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

1 stock market mistake to avoid in 2025

This Fool has been battling bouts of of FOMO recently, as one of his growth shares enjoys a big bull…

Read more »

Investing Articles

2 no-brainer buys for my Stocks and Shares ISA in 2025

Harvey Jones picks out a couple of thriving FTSE 100 companies that he's keen to add to his Stocks and…

Read more »

Number three written on white chat bubble on blue background
Investing For Beginners

3 investing mistakes to avoid when buying UK shares for 2025

Jon Smith flags up several points for investors to note when it comes to thinking about which UK shares to…

Read more »

Investing Articles

Will the rocketing Scottish Mortgage share price crash back to earth in 2025?

The recent surge in the Scottish Mortgage share price caught Harvey Jones by surprise. He was on the brink of…

Read more »

Investing Articles

2 cheap shares I’ll consider buying for my ISA in 2025

Harvey Jones will be on the hunt for cheap shares for his ISA in 2025 and these two unsung FTSE…

Read more »